Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced it will
Specialist pharmaceutical services clinical research company Open Orphan has appointed Yamin ‘Mo’ Khan as its chief executive with immediate effect. Mr Khan joined the company’s board as a non-executive director
Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announced today the appointment of Yamin
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for a vaccine candidate for respiratory syncytial virus (RSV). Bavarian Nordic’s MVA-BN RSV was granted the designation, which
Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, noted today the announcement dated 14
Each journey begins at a starting point, and we believe that few journeys are as exciting as developing a drug. In order to succeed and reach your destination, you need
Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has noted the
Healthy, young people who were intentionally exposed to the coronavirus SARS-CoV-2 developed mild symptoms — if any — in a first-of-its-kind COVID-19 human-challenge study. Such trials present a unique opportunity
Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO, a subsidiary
Open Orphan’s Cathal Friel discusses the results from the COVID-19 characterisation study, the next phase of the human challenge programme and whether we can expect COVID-19 revenue this year in this exclusive interview with DirectorsTalk.
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
